Abstract
Gene therapies are innovative treatments that could revolutionize healthcare. Given their unique mechanisms of action, methods of manufacturing and administration, and the potential for long-lasting impact, gene therapies require long-term follow-up (LTFU) of safety and effectiveness post-authorization, often using real-world data (RWD). With over 2000 gene therapies in development, there is a need for knowledge-building regarding LTFU studies. Here, we review regulatory, scientific, and operational requirements and considerations for LTFU studies using RWD from a global perspective. The insights in this review support post-authorization LTFU studies for gene therapies, thereby contributing to their safe and effective use.
| Original language | English |
|---|---|
| Article number | 104337 |
| Number of pages | 11 |
| Journal | Drug Discovery Today |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2025 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- effectiveness
- efficacy
- gene therapy
- long-term follow-up
- pharmacoepidemiology
- real-world data
- safety
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver